Dr. Rod BREMNER / Exploiting CRISPR screens to deduce tumor suppressor functions and drug resistance mechanisms.
vendredi 25 mai - 11:00 à 12:30
Dr. Rod BREMNER, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada
Genome-wide CRISPR screens are transforming insight into gene function in mammalian cells. We are using this approach to deduce tumor suppressor mechanisms and to understand mechanisms of cancer drug resistance. Our work addresses tumor suppressor action in multiple RB deficient cancers, such as small cell lung cancer, retinoblastoma, and aggressive neuroendocrine prostate cancer, as well as the mechanism of action of drugs such as the Neddylation inhibitor MLN4924 (Pevonedistat) alone or in combination with the classic chemotherapeutic agent Topotecan, and the first line therapy for Acute Myeloid Leukemia (AML), ara-C (Cytarabine). Hit validation rates are high and provide new mechanistic insight into cancer progression, treatment and drug resistance.